BioSciences Research Associates, Inc

Invivotek LLC, a member of Genesis Biotechnology Group® (GBG) is a global pre-clinical contract research organization (CRO) specializing in small animal studies for drug discovery and early optimization. Invivotek's facility was opened in 2012 and our first commercial project launched in 2013.

Invivotek offers both custom and standard pre-clinical services for drug discovery and development programs for our clients. Invivotek’s portfolio includes animal models and bioassays designed to support in vivo testing of compounds related to Immunology and Inflammation, Oncology, Metabolic, and Cardiovascular diseases. Invivotek’s in vivo testing capabilities are supported by biochemical and molecular biology techniques as well as functional assays with primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study the mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers. The collective experience across multiple therapeutic areas in conjunction with the business and project management skills of the team working in a state-of-the-art animal facility, position Invivotek as a leading provider of preclinical in vivo services.

Multispan, Inc. is a premier assay screening technology provider targeting GPCRs, kinases and beyond using endogenously expressed targets in primary cells and recombinant stable cell lines. It has created the industry’s largest, highly characterized, highest quality GPCR-expressing stable cell lines and assays based on cell signaling and phenotypic biology. Multispan offers integrated high quality solutions in assay development, HTS and SAR lead optimization screening support to shorten time to IND and discover better medicine in cardiovascular, metabolic, CNS, inflammation, immunology and oncology diseases. Multispan’s high standard of quality and integrity has earned successful long-term collaborations with a wide range of leading pharmaceutical and biotech companies globally.

Redoxis is a preclinical boutique CRO specializing on inflammation and autoimmune conditions. We provide in vivo, ex vivo and in vitro preclinical efficacy and MoA studies. We have a fully equipped lab with capacity to perform a wide range of cell based assays as well as immunology assays to provide you everything form MoA studies to PK and in vivo efficacy studies.

YOLARX is world-renown for its scientific excellence in pharmacoepidemiology, pharmacovigilance, and therapeutic risk management. 

Since its founding in 2006, YOLARX has developed and integrated an unique approach as it spans the product life-cycle following a roadmap which corresponds to the changing environment of drug regulation and reimbursement.

Our goal is to provide expertise and research of the highest methodological standards that evaluate the benefits and risks of medicines in the real-world, for a global client base.

Therapeutic areas in which YOLARX has worked include neuro-psychiatry, cardiovascular and metabolic disease, infectious disease, hematology/oncology, immunology/inflammation, pain, ophthalmology, dermatology, pulmonary disease, vaccinology, rare disease and biosimilars, …

To learn more about YOLARX Consultants, please visit: www.yolarx.com.

Haematologic Technologies (HT) is a large molecule CRO unlike any other. Combining world-class protein chemistry expertise, integrated large molecule analytical services, and customized products to support biopharma R&D, we accelerate large molecule drug development for clients around the globe.

HT’s services are offered from discovery through commercial GMP release of large molecule therapeutics. Not your typical large molecule CRO, HT has a specific depth of expertise in large molecule analytics, manufacturing process support, and navigation of the complex regulatory pathways from IND to BLA. Our services de-risk and speed your new drug development process.

Our scientific experts are well known in the fields of protein chemistry, advanced High Resolution Mass Spec (HRMS), Immunology, hemostasis, and novel assays to support complex large molecule therapeutic development and manufacture. Our FDA-inspected facilities operate to the highest standards of GMP compliance.

Building on our 30+ years of expertise in plasma proteins, hemostasis and blood coagulation, HT is also a leading global supplier of coagulation research reagents (plasma proteins and antibodies), custom formulated IVD/POC device reagents, as well as customized blood collection tubes to support clinical trials.

Visit us at www.haemtech.com.